Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind trial of 9-valent HPV vaccine versus GARDASIL in young men
NL-OMON40129Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Apr 2014
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in human papillomavirus infection comparing V503 with GARDASIL (2 arms). Primary endpoint: Immunogenicity. Started Apr 2014; status: active, not recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccineqHPV vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NL-OMON40129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40129.